The Privacy Delusions Of Genetic Testing

  • Forbes | by: Peter J. Pitts |
  • 02/15/2017
Genetic testing promises a revolution in healthcare. With just a few swabs of saliva, diagnostics can provide an unprecedented look into a person's family history and potential health risks.

Within a decade, global sales of genetic tests are expected to hit $10 billion. Direct-to-consumer companies such as 23andMe and Genos have proven particularly popular, with tens of thousands of people purchasing at-home testing kits every year.

But the industry's rapid growth rests on a dangerous delusion: that genetic data is kept private. Most people assume this sensitive information simply sits in a secure database, protected from hacks and misuse.

Far from it. Genetic-testing companies cannot guarantee privacy. And many are actively selling user data to outside parties.

The problem starts with the Health Insurance Portability and Accountability Act (HIPAA), a 1996 federal law that allows medical companies to share and sell patient data if it has been "anonymized," or scrubbed of any obvious identifying characteristics.

 
Sign Up for Our Email Newsletter

RECENT NEWS

War on Vaping Threatens Public Health

War on Vaping Threatens Public Health

Will the government hamstring what is potentially the most important public health innovation of the 21st century?...  Read more

PBMs Are Hogging Our Drug Discounts

PBMs Are Hogging Our Drug Discounts

PBMs are knowingly profiting off the backs of American patients, pharmacists, and innovators....  Read more

Advancing 21st Century Pain Management Conference (August 17, 2018)

Advancing 21st Century Pain Management Conference (August 17, 2018)

CMPI conference: Advancing 21st Century Pain Management Keynote Speaker: FDA Commissioner Scott Gottlieb...  Read more

DRUGWONKS BLOG